Oncotarget

Research Papers:

Prognosis of surgery combined with different adjuvant therapies in esophageal cancer treatment: a network meta-analysis

Shenglei Li _, Hongtao Liu, Changying Diao, Xiaohui Wang, Ming Gao, Zongming Li, Lijie Song, Xianzheng Gao, Jing Han, Feng Wang, Wencai Li and Xinwei Han

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:36339-36353. https://doi.org/10.18632/oncotarget.16193

Metrics: PDF 1852 views  |   HTML 2114 views  |   ?  


Abstract

Shenglei Li1,*, Hongtao Liu2,*, Changying Diao1, Xiaohui Wang1, Ming Gao3, Zongming Li4, Lijie Song3, Xianzheng Gao1, Jing Han1, Feng Wang3, Wencai Li1 and Xinwei Han4

1Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 50000, China

2Laboratory for Cell Biology, College of Life Sciences of Zhengzhou University, Zhengzhou, Henan, 450001, China

3Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China

4Department of Interventional Therapy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China

*These authors have contributed equally to this work

Correspondence to:

Feng Wang, email: [email protected]

Xinwei Han, email: [email protected]

Keywords: esophageal cancer, surgery, adjuvant therapies, chemotherapy, radiotherapy

Received: September 09, 2016    Accepted: February 20, 2017    Published: March 14, 2017

ABSTRACT

This network meta-analysis was conducted to assess whether the efficacy of surgery with adjuvant therapies, including radiotherapy (RT+S), chemotherapy (CT+S), and chemoradiotherapy (CRT+S) have better performance in esophageal cancer treatment and management. PubMed and EMBASE were used to search for relevant trials. Both conventional pair-wise and network meta-analyses were carried out. The surface under the cumulative ranking curve (SUCRA) was used to rank interventions based on the efficacy of the treatment method. As for 3-year overall survival (OS), CRT+S showed the highest efficacy (CRT+S vs. surgery: HR=0.81, 95% CrI =0.73-0.90; CRT+S vs. CT+S: HR=0.82, 95% CrI =0.70-0.95; CRT+S vs. RT+S: HR=0.77, 95% CrI =0.62-0.95). For disease-free survival, CRT+S showed efficacy over CT+S ((HR =0.70, 95% CrI =0. 59-0.83). In conclusion, CRT+S showed a better performance for survival outcomes and ranks best among all therapies. The results of our study can provide guidance for medical decisions and treatment options that may help clinical practitioners improve the efficacy of EC treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16193